Brief: SpringWorks Therapeutics Says Co To Pay Merck KGaA $145.6 Million Termination Fee If Deal Is Terminated Under Some Circumstances
April 28 (Reuters) - Merck KGaA MRCG.DE: SPRINGWORKS THERAPEUTICS: CO TO PAY MERCK KGAA $145.6 MILLION TERMINATION FEE IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES Source text: [ID:n0001104659-25-039627] Further company coverage: MRCG.DE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN